Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.4% Following Insider Selling

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) traded down 4.4% on Tuesday after an insider sold shares in the company. The stock traded as low as $12.10 and last traded at $12.10. 38,531 shares changed hands during mid-day trading, a decline of 49% from the average session volume of 75,509 shares. The stock had previously closed at $12.66.

Specifically, President Songjiang Ma sold 2,000 shares of the stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the sale, the president now directly owns 2,928,467 shares of the company’s stock, valued at approximately $37,191,530.90. This represents a 0.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Gyre Therapeutics Price Performance

The business’s 50-day simple moving average is $12.71 and its 200-day simple moving average is $12.66.

Institutional Investors Weigh In On Gyre Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its stake in shares of Gyre Therapeutics by 392.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after purchasing an additional 90,557 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Gyre Therapeutics by 16.9% in the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after buying an additional 43,840 shares during the last quarter. Advantage Alpha Capital Partners LP bought a new stake in shares of Gyre Therapeutics during the 3rd quarter worth about $334,000. WINTON GROUP Ltd acquired a new position in shares of Gyre Therapeutics during the 2nd quarter valued at about $220,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Gyre Therapeutics in the 2nd quarter valued at approximately $218,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.